🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Women in Lymphoma - [email protected] breakfast at #ASH24. Truly inspiring meeting and so happy to be a part of WiL!

📣 THE MAIN SCIENTIFIC TOPICS OF #ESHCART2025! Register here ➡️ bit.ly/3TExODA 3rd How I Manage #CART Therapies & Bispecific Antibodies for My Patients Chairs: Caron Jacobson, Ulrich Jäger, MarieJosé Kersten 🗓️ September 26-28, 2025 in Stockholm, Sweden 🇸🇪 #ESHCONFERENCES

My group is expanding! Position available for a PhD student in computational biology/bioinformatics to work on a goldmine of data from neoadj IO trials using the newest techniques! Click below for more info. nki.nl/careers-study/…

📣 READ THE LEARNING OBJECTIVES OF #ESHCART2025! Register here ➡️ bit.ly/3TExODA 3rd How I Manage #CART Therapies & Bispecific Antibodies for My Patients Chairs: Caron Jacobson, Ulrich Jäger, MarieJosé Kersten 🗓️ Join us on September 26-28, 2025 in Stockholm 🇸🇪 #ESHCONFERENCES

📣 #CART25 is getting closer! 🤩 Next week, we're getting together with the international CAR T community in 📍 Strasbourg, France, to explore the latest in CAR T-cell therapy. There is still time to book your spot and join in person or virtually! Additional discounts are

#T2EVOLVE aims to accelerate access to CAR T-cell Therapy across Europe. Through heartfelt patient stories, expert interviews, and resources, we offer patients an open access, central place to learn about what they can expect from this innovative treatment and how to navigate its

We congratulate #T2EVOLVE Project Managers Elise Pennings and Maik Luu on each receiving a 5th Emerging Investigators #EHA-EBMT Joint Fellowship Awards in the Field of Cell Therapy and Immunotherapy at #CART25 on patient reported outcomes of CAR T-cell therapy and

Don´t miss this episode featuring 2 amazing WiL decoding T cell lymphomas and sharing their expert opinions and experience.

Today, on International Women´s day, we celebrate the resilience, brilliance, and determination of women breaking barriers, advancing research, and mentoring the next generation of innovators and leaders. #InternationalWomensDay #WomenInLymphoma

📣 #ESHCART2025 REMINDER Abstract submission is OPEN! For more information➡️bit.ly/3TExODA 3rd How I Manage #CART Therapies & Bispecific Antibodies for My Patients Chairs: Caron Jacobson, Ulrich Jäger, MarieJosé Kersten Sept. 26-28, 2025 in Stockholm, Sweden 🇸🇪 #ESHCONFERENCES

Looking for patient-friendly information about CAR T-cell treatment? The T2EVOLVE Patient Hub offers valuable information about this ground-breaking treatment, available in six different languages. Gain insights through our explainer videos for patients and caregivers. 🔗

A sincere thank you to the T2EVOLVE Work Group for Patients and Caregivers (WGPC)! T2EVOLVE is committed to providing patient-centered information on the innovative CAR T-cell treatment.  The Work Group for Patients and Caregivers (WGPC) plays a crucial role in defining content

Superior survival in diffuse large B cell lymphoma of the bone with immune rich tumor microenvironment Blood Cancer Journal nature.com/articles/s4140…

HAVE YOU CHECKED THE MAIN SCIENTIFIC TOPICS OF #ESHCART2025? Learn more ➡ bit.ly/3TExODA 3rd How I Manage #CART Therapies & Bispecific Antibodies for My Patients Sept 26–28, 2025 Stockholm Chairs: Caron Jacobson, Ulrich Jäger, MarieJosé Kersten #ESHCONFERENCES #MMsm #Lmsm

Peripheral T- and natural killer-cell lymphomas: ESMO–EHA Clinical Practice Guideline for diagnosis, treatment and follow-up☆ - Annals of Oncology annalsofoncology.org/article/S0923-…

Just landed Report of Consensus Panel 3 from the 12th International Workshop on Waldenström’s Macroglobulinemia on the management of patients with high-risk disease authors.elsevier.com/a/1lAWr8THnlHEn Mayo Myeloma MarieJosé Kersten Thanos Dimopoulos

#Myeloma Paper of the Day: Consensus Panel 3 from 12th International #Waldenström macroglobulinemia Workshop recommends risk stratifying smoldering & active WM, genetic alteration screening & risk-adapted approach w/ clinical trial participation: pubmed.ncbi.nlm.nih.gov/40441983/. #mmsm

#ESHCART2025 3 WEEKS LEFT FOR ABSTRACT & CLINICAL CASES SUBMISSION! Proceed now➡️bit.ly/3TExODA 3rd How I Manage #CART Therapies & Bispecific Antibodies for My Patients Sept 26–28, 2025 Stockholm Chairs: Caron Jacobson Ulrich Jäger MarieJosé Kersten #ESHCONFERENCES #MMsm #Lmsm